Results 131 to 140 of about 64,314 (239)

Etanercept in the Treatment of Vitiligo

open access: yesDermatology, 2007
Rigopoulos, Dimitris   +5 more
openaire   +3 more sources

Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction

open access: yesObesity Reviews, Volume 27, Issue 12, December 2026.
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey   +7 more
wiley   +1 more source

Consistency of skin clearance with icotrokinra across patient subgroups with plaque psoriasis

open access: yes
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Linda Stein Gold   +13 more
wiley   +1 more source

Associations of Rheumatoid Arthritis Disease Activity With Frailty Over Five Years of Follow‐up

open access: yesArthritis Care &Research, Volume 78, Issue 11, Page 1759-1768, November 2026.
Objective To evaluate whether rheumatoid arthritis (RA) disease activity is associated with frailty both in cross‐section and longitudinally. Methods Participants within the Veterans Affairs Rheumatoid Arthritis (VARA) registry enrolled from 2003 to 2022 were included.
Courtney N. Loecker   +14 more
wiley   +1 more source

Etanercept Combined with Glucocorticoid and Gamma Globulin for Treating Children with Toxic Epidermal Necrolysis: A Case Report

open access: yes
Yanhua Fu,1 Yuanyuan Xiao,2 Tianji Gao,1 Junxiu Zhang,3 Tianjiao Wang1 1Department of Rheumatology, Baoding Hospital of Beijing Children’s Hospital, Baoding, 071000, People’s Republic of China; 2Department of Dermatology, National Center for Children’s ...
Zhang J, Xiao Y, Wang T, Fu Y, Gao T
core  

Neighborhood Socioeconomic Status and Short‐Term Functional Outcomes in Systemic Lupus Erythematosus

open access: yesArthritis Care &Research, Volume 78, Issue 11, Page 1640-1649, November 2026.
Objective Individuals with systemic lupus erythematosus (SLE) can accumulate functional status (FS) impairment. We evaluated the association between neighborhood socioeconomic disadvantage, as measured by the Area Deprivation Index (ADI), and FS in a national SLE sample.
Baljeet Rai   +7 more
wiley   +1 more source

Real‐World Trends in Prenatal Antirheumatic Drug Utilization in Ontario, Canada: A Cross‐Sectional Time‐Series Analysis

open access: yesArthritis Care &Research, Volume 78, Issue 11, Page 1801-1810, November 2026.
Objective This study aimed to describe real‐world trends in preconception and prenatal use of antirheumatic drugs among pregnant individuals with rheumatic diseases in Ontario, Canada. Methods We conducted a time‐series analysis using repeated cross‐sectional data to examine annual patterns of disease‐modifying antirheumatic drug (DMARD) use among ...
Shenthuraan Tharmarajah   +6 more
wiley   +1 more source

Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data

open access: yesBMC Rheumatology
Background Safety remains a significant concern for biologic drugs, and studies are needed to ensure a comparable safety profile for biosimilars and their legacy treatments.
Marina G. Birck   +7 more
doaj   +1 more source

Clinical Features, Treatments, and Outcomes of an International Cohort of 96 Children with Takayasu Arteritis

open access: yesACR Open Rheumatology, Volume 8, Issue 11, November 2026.
Objective To characterize the clinical features, treatment, and outcomes of a large, international cohort of childhood‐onset Takayasu arteritis (cTAK). Methods Patients with a diagnosis of cTAK were identified in A Registry of Childhood Vasculitis and divided into subcohorts by era‐of diagnosis: pre‐biologic (PB; 1986–2006), early biologic (EB; 2007 ...
James Bistolarides   +29 more
wiley   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2261-2273, November 2026.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy